Cytomegalovirus (CMV) infections are associated with vascular diseases in the human population. We have previously shown vascular dysfunction in systemic and uterine arteries dissected from nonpregnant (NP) mouse CMV (mCMV)-infected mice that was further impaired during late pregnancy (LP). CMV attachment alone through glycoprotein B (GB) can generate signals that impact vascular tone regulation. However, the contribution of direct virus interactions with endothelium to the vascular dysfunction we previously observed after in vivo mCMV infection is not known. We used a pressure myograph system to infuse GB or whole intact mCMV inside arteries dissected from uninfected mice and assessed vasodilation to methacholine infused inside pressurized arteries rather than applied abluminally. These results were compared to those observed after methacholine infusion into untreated arteries dissected from mCMV-infected mice. In mesenteric arteries, vasodilation to infused methacholine did not differ among treatments in NP or LP groups in contrast to previously published studies. However, increased vasoconstrictor activity was unmasked after blocking thromboxane receptors or prostaglandin production. Vasodilation in uterine arteries from uninfected NP mice to infused methacholine was increased by both GB and whole intact mCMV pretreatment. Untreated uterine arteries from mCMV-infected NP mice showed even greater vasodilation. There was no effect of GB or whole intact mCMV pretreatment in uterine arteries from uninfected LP mice, whereas vasodilation to infused methacholine was reduced in untreated uterine arteries from mCMV-infected LP mice. CMV exerts direct effects on vascular function which should be considered during viral reactivation leading to viremia and during GB-based vaccine administration.
INTRODUCTION
Human cytomegalovirus (HCMV), a mammalian speciesspecific Herpes virus, infects 40-80% of the human population [1] . Like other Herpes viruses, HCMV cycles between latent and active phases as a lifelong infection. Active or reactivated HCMV infections may affect the vasculature during times of stress [2] , immune suppression [3] , and/or pregnancy [4] . HCMV is associated with several vascular diseases, including atherosclerosis, coronary heart disease, and vasculopathy [5] [6] [7] . During pregnancy, HCMV infections have also been associated with the hypertensive disorder preeclampsia [7] [8] [9] .
Systemic and local blood pressure is regulated by many factors, including those that control vascular tone. Vascular tone develops from a balance between vasodilatory and vasoconstrictory influences. Several circulating factors impact the production of vasodilators and vasoconstrictors by the endothelium that then interact with the underlying smooth muscle cells in intact arteries to regulate vascular tone and ultimately blood pressure. The endothelium also acts as a barrier to prevent free access of many circulating substances to the underlying tissues. Our laboratory uses a specialized system to which dissected arteries can be mounted, pressurized, and then exposed to vasoactive factors either by infusion inside the vessel (intraluminal) where they directly interact with endothelium or by application to the outside the vessel (extraluminal) where they first encounter vascular smooth muscle cells. We previously showed that vasodilation to extraluminally applied methacholine (ME), a cholinergic agonist, was increased in mesenteric arteries dissected from nonpregnant (NP) and late pregnant (LP) mice with an active in vivo mCMV infection and also in uterine arteries from mCMVinfected NP mice. In contrast, there was greatly decreased extraluminal ME-induced vasodilation in uterine arteries from mCMV-infected LP mice compared to uninfected mice [10, 11] . We also found that vascular endothelial and smooth muscle cells in mesenteric and uterine arteries dissected from mCMV-infected mice were directly infected [11] . However, the contribution of the direct interaction of virus or its coat proteins with the endothelium of an intact artery to changes in vascular function independent of a systemic viral infection and immune response is not known.
The initial binding of CMV to the cell surface alone induces rapid intracellular signals leading to production of reactive oxygen intermediates, prostaglandin synthesis, and induction of interferon-inducible genes through activation of kinases and transcription factors, eventually leading to increased inflammatory cytokine gene expression, all of which can affect vascular function [12, 13] . These cellular responses do not require viral replication [14] . Glycoprotein B (GB) is one of several viral envelope glycoproteins involved in CMV attachment and entry into cells [15] [16] [17] [18] . GB is conserved in several Herpes viruses [18] and is the major subunit that is targeted in vaccination trials [19] [20] [21] [22] . GB is specifically involved in viral attachment and fusion to the cell surface following initial tethering of the virus to heparan sulfate proteoglycans [16] . The host cell receptors required for CMV attachment and entry that GB binds to are still being established; however, epidermal growth factor receptor, tolllike receptors, and integrins are cell-specific candidates [16, [23] [24] [25] . On attachment, GB triggers cellular transcription to prepare the cell for CMV infection [14, 26] . This includes an increase in NF-jB activity leading to an increase in inflammatory cytokines [13, 27] , such as tumor necrosis factor (TNF)-a and interferon (IFN)-c, which can affect vascular responses and have been associated with vascular diseases [28] . Understanding how viral attachment alone can affect vascular responses compared to a full systemic infection is important in determining how early and to what extent vascular function is impacted during the acute stage of a primary infection or during reactivation of a latent infection when viremia is more likely to be present. This information is crucial to help identify potential therapeutic targets that may attenuate the initial and direct effects of CMV on vascular function.
Given the cyclical nature of CMV infections and documentation of reactivation in times of stress including pregnancy, the potential vascular impact of the rapid cellular responses to viral attachment alone, and the importance of GB to vaccine development [29] [30] [31] , our objectives were to determine how direct interactions of virus or GB with endothelium contribute to altered vascular responses in comparison to the effects of a systemic infection. We hypothesized that short-term exposure of the endothelium of pressurized intact arteries dissected from uninfected NP mice to either GB protein or whole intact virus will increase endothelium-dependent vasodilation to a similar extent as the increase found in untreated arteries from mCMVinfected compared to control mice [10, 11] . In addition, pretreatment with GB or whole intact virus in pressurized uterine arteries dissected from uninfected LP mice will decrease vasodilation similarly to our previous findings in uterine arteries from mCMV-infected LP mice [10, 11] . In this study we also investigated vasodilation by infusing ME inside pressurized arteries, where it interacts directly with the endothelium, rather than applying ME to the bath or the outside of the artery, where it reaches the endothelium only after interacting with the smooth muscle cells first.
MATERIALS AND METHODS

Animal Model and Tissue Collection
Virgin C57Bl/6J 2-to 5-mo-old female mice were purchased from Jackson Laboratories and housed in Health Sciences Laboratory Animal Services at the University of Alberta. Half of the mice (numbers indicated in each figure legend) were infected with 10 6 plaque-forming units of mCMV (RM427þ; gift from E. Mocarski, Stanford University, Stanford, CA [32] ) by intraperitoneal injection as described previously [11] . RM427þ contains a gene insertion for b-galactosidase (LacZ gene) in the nonessential immediate early 2 gene to allow detection of infectious virus by assessing b-galactosidase activity. Following a 5-day observational period, infected NP mice were either 1) euthanized by cervical dislocation 5-21 days after injection or 2) bred 5-12 days after injection to male C57Bl/6J mice. This ensured that all infected mice were studied within 1 mo of infection. Since infectious virus is still detectable in this time frame [33] , it is unlikely that the results of this study were influenced by differences in length of time between viral injection and euthanization. Breeding of both mCMV-infected and uninfected mice was done overnight, and the presence of a vaginal plug was confirmed the next day (Day 0.5 of gestation [D0.5]). Controls were age-matched uninfected NP or LP mice. LP mice were euthanized on D18.5; delivery normally occurs on D19.5 in C57Bl/6J mice. The mesentery and uterine horns with intact vasculature were isolated from each mouse and immediately placed in cold HEPES-buffered physiological saline solution (PSS; 10 mM HEPES, 1.56 mM CaCl 2 , 142 mM NaCl, 4.7 mM KCl, 1.18 mM KH 2 PO 4 , 1.17 mM MgSO 4 , and 5.5 mM glucose at pH 7.5). These animal protocols were approved by the University of Alberta Animal Welfare Committee and followed the guidelines outlined by the Canada Council of Animal Care.
Pressure Myograph Studies
Second-order mesenteric and main uterine arteries were dissected free of fat and adipose tissue. Prior to mounting a single artery, the tubing leading to one glass cannula was loaded with 290 ll of PSS with or without GB (1 lg/ml) or whole intact mCMV (;10 multiplicity of infection [MOI] or 10 virions per cell) followed by 2 cm of air and a second solution (200 ll) that consisted of either a single dose of ME diluted in PSS, PSS alone (control), or fibroblast cell culture medium obtained by filtering out the virus with a 0.1-lm filter (filtered virus control). The 2-cm air bubble loaded between each solution was too small to pass the transducer and reach the vessel but was large enough to prevent mixing of the solutions in the tubing. The reagents were then pumped through the tubing until the lead of PSS with or without GB or whole intact mCMV pretreatment reached the end of the glass cannula (no air) and the 2-cm air bubble reached just before the transducer. One end of the artery was then mounted onto the opposite cannula to flush out the residual blood, and then the other end was tied onto the cannula attached to the loaded tubing in a PSS-filled bath in a dual chamber arteriograph (Living Systems Instrumentation) as previously described [11] . The vessel was then pressurized to 60 mm Hg (mesenteric arteries) or 50 mm Hg (uterine arteries) [11, 34, 35] by equilibrating for 10 min at 20 mm Hg, 10 min at 40 mm Hg, and 10 min at the final pressure (60 or 50 mm Hg) with length adjustments to remove kinks in the vessel. The bath was replaced with PSS every 10 min. Arteries in which pressure was unable to be maintained were discarded and replaced with new vessels from the same animal. The bath temperature was maintained at 378C. Lumen diameter was measured digitally using a video dimension analyzer (Living Systems Instrumentation).
Experimental Design
Following the 30-min pressurization steps, a low flow (30 ll/min) was administered to arteries for 20 sec every 10 min over a 30-min to 1-h period to allow viral attachment/early entry (no significant difference was observed between the two time points). Arteries were then preconstricted to approximately 50% with the addition of the thromboxane (TBXA2)/ prostaglandin H 2 (PGH2) mimetic U46619 (Calbiochem) to the bath. Flow was resumed for 9 min (PSS solution) and stopped for 3 min, and the lumen diameter was recorded. Flow was then again resumed for approximately 7 min (until the single dose of ME reached the artery) and stopped for 3 min, and lumen diameter was again recorded. Each dose of ME was infused into a single artery, and multiple arteries from each animal were used to obtain results for all ME doses tested (1 nM-10 lM).
Pretreatment of arteries from uninfected mice with either GB or whole intact mCMV led to similar ME-induced vasodilation; therefore, the following inhibitor experiments were performed on arteries pretreated with GB only. To determine the effect of vasoconstrictory prostanoids on vascular tone after ME infusion, mesenteric arteries from uninfected mice pretreated with or without GB or mesenteric arteries from mCMV-infected mice were then exposed to the prostaglandin-endoperoxide synthase 1/2 (PTGS1/2) inhibitor meclofenamate (1 lM; Sigma-Aldrich) or the TBXA2/PGH2 receptor antagonist SQ29548 (10 lM; Cayman Chemical) by addition to the bath. This was followed by preconstriction to approximately 50% with U46619 (meclofenamate) or PE (SQ29548) and then intraluminal infusion of the vasodilator ME (1 lM). To determine if the effects of viral attachment or infection on vasodilation in uterine arteries were specific to the cholinergic system, bradykinin (1 lM; Sigma-Aldrich) was also tested. The percent dilation was calculated as L2-L1/ L1 3 100, where L1 is the initial lumen diameter after pretreatment by flow with PSS in the presence or absence of GB or whole intact mCMV and L2 is the lumen diameter after flow with ME, bradykinin, PSS control, or filtered virus control. The percent dilation was then normalized to the vessel diameter when fully relaxed at the same pressure (passive lumen diameter) in Ca 2þ -free EGTA PSS (10 mM HEPES, 142 mM NaCl, 4.7 mM KCl, 1.18 mM KH 2 PO 4 , 1.17 mM MgSO 4 , 2 mM EGTA) with 100 lM of papaverine (Sigma-Aldrich) for 10 min [11] .
Statistics
Vascular responses were averaged and compared between treatments (mCMV-infected and uninfected 6 GB or mCMV) and ME concentrations (1 nM-10 lM) using multiple two-way analyses of variance (ANOVAs) followed by Bonferroni post hoc analysis to determine significance. It is important to note that ME was not infused in cumulative doses in a single artery; rather, a single dose was always infused into a single artery. As such, data were presented in a bar graph rather than in a dose-response line graph as done in previous studies [10, 11] . Vascular responses with different treatments (ME 6 meclofenamate or SQ29548; bradykinin) were averaged and compared between groups (mCMV-infected and uninfected 6 GB) using a one-way ANOVA followed by Bonferroni post hoc analysis to determine significance. Significance was accepted at P , 0.05.
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RESULTS
Endothelium-Dependent Vasodilation in Mesenteric Arteries from Uninfected Mice Pretreated with or Without GB or Whole Intact mCMV Compared to That Found in Untreated Arteries from mCMV-Infected Mice
An important aspect of these experiments was the ability to infuse GB or whole intact mCMV inside isolated and dissected arteries mounted on a pressure myograph system at a slow rate using a small pump to allow direct interactions with the endothelium. We also chose to use a more physiological measure of endothelium-dependent vasodilation by infusing ME, a single concentration at a time, into intact pressurized arteries (intraluminal), where it interacts directly with the endothelium rather than by addition to the bath (extraluminal), as performed previously [10, 11] , where it accesses the endothelium only after first interacting with the smooth muscle cells.
Vasodilation to infused ME (0.1 lM-10 lM) did not differ among mesenteric arteries from uninfected NP or LP mice pretreated with GB or whole intact mCMV or those untreated from mCMV-infected mice compared to untreated arteries from uninfected mice (controls). Vasodilation was absent in preconstricted arteries from uninfected mice infused with PSS alone or filtered virus control (data not shown) at the same flow rate as ME infusion (Fig. 1, A and B) . Pretreatment of mesenteric arteries with either GB or whole intact mCMV led to similar ME-induced vasodilation, so the following experiments were performed only on mesenteric arteries pretreated with GB.
Contribution of TBXA2/PGH2 to Endothelium-Dependent Vasodilation in Mesenteric Arteries
Our previously published results demonstrated an increase in vasodilation as assessed by extraluminal addition of ME on mesenteric arteries from mCMV-infected compared to uninfected NP and LP mice [10] . This was not seen in the current study (Fig. 1, A and B) . To determine if the lack of increased vasodilation to intraluminally infused ME was due to an increased production or activity of TBXA2/PGH2, we inhibited PTGS1/2 or the TBXA2 receptor with meclofenamate or SQ29548, respectively, in mesenteric arteries from uninfected mice treated with or without GB or in mesenteric arteries from mCMV-infected NP and LP mice. Both meclofenamate and SQ29548 pretreatments led to increased ME-induced vasodilation in mesenteric arteries from uninfected mice treated with GB and in arteries from mCMV-infected mice compared to controls (Fig. 2) .
Endothelium-Dependent Vasodilation in Uterine Arteries from Uninfected Mice Pretreated with or Without GB or Whole Intact mCMV Compared to That Found in Untreated Arteries from mCMV-Infected Mice
In uterine arteries from uninfected NP mice, pretreatment with either GB or whole intact mCMV significantly increased vasodilation induced by intraluminally infused ME at 0.1 lM and 1 lM compared to controls; however, vasodilation at the maximum ME concentration did not differ among the groups. Similarly to the GB-or mCMV-treated arteries, untreated uterine arteries dissected from mCMV-infected NP mice also showed increased vasodilation to infused ME at 0.1 lM compared to controls. However, at 1 and 10 lM of infused ME, untreated uterine arteries from mCMV-infected NP mice showed significantly greater vasodilation compared to GB-or mCMV-treated arteries from uninfected mice. Vasodilation was absent in the preconstricted uterine arteries, where only PSS or filtered virus control were infused ( Fig. 3A; data not shown).
In uninfected LP mice, there were no differences in response to infused ME in uterine arteries treated with GB or whole intact mCMV compared to untreated controls (Fig. 3B) . However, in uterine arteries from in vivo mCMV-infected LP mice, vasodilation to infused ME was significantly reduced between 0.1 and 10 lM of ME. Vasodilation was absent with FIG. 1. Effect of short-term pretreatment of pressurized mesenteric arteries with GB or mCMV on vasodilation induced by infusion of ME. Mesenteric arteries dissected from uninfected NP (A) and LP (B) mice were infused with PSS, 1 lg/ml of GB, or whole intact mCMV at an MOI of 10. Mesenteric arteries dissected from mCMV-infected mice were infused with PSS only. After a 30-min to 1-h incubation, all arteries were preconstricted with U46619 followed by infusion of a single concentration of ME. This was repeated for each ME concentration from 1 nM to 10 lM. Data were expressed as the mean 6 SEM percent increase in arterial lumen diameter compared to the passive lumen diameter in the presence of Ca 2þ -free medium and papaverine. No significant difference among treatments at each dose was found by two-way ANOVA and Bonferroni post hoc analysis. n ¼ 3-8 animals.
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PSS alone or the filtered virus control ( Fig. 3B ; data not shown).
Vasodilation to Bradykinin in Uterine Arteries
To determine if the altered sensitivity to infused ME in response to GB pretreatment of uterine arteries from uninfected mice or those from in vivo mCMV-infected mice is specific to activation of the muscarinic receptors by the cholinergic agonist ME, another vasodilator that acts through a different receptor was used. Bradykinin was infused into preconstricted uterine arteries from uninfected mice with or without GB pretreatment or into uterine arteries from mCMV-infected NP and LP mice. We found no increase in bradykinin-induced vasodilation in GB pretreated uterine arteries from uninfected mice or those from mCMV-infected mice compared to controls (Supplemental Fig. S1 , available online at www.biolreprod. org).
DISCUSSION
HCMV infections are associated with vascular dysfunction and diseases, including atherosclerosis and preeclampsia [7] . CMV attachment alone to cell surface receptors induces intracellular signaling pathways that may affect vascular function [13] . The novel findings of this study are that direct exposure of endothelial cells in intact pressurized arteries to GB protein or whole intact mCMV for up to 1 h impacts vascular responses independently of an in vivo systemic infection, which can exacerbate the effects of direct exposure. The short exposure time likely leads to viral attachment and possibly early entry but is not sufficient time for CMV viral gene expression, replication, or egress, given the long replication cycle (up to 48-72 h) [36] . Although there were no differences in vasodilation responses to infused ME in GBtreated mesenteric arteries from uninfected NP mice or those from mCMV-infected mice, we revealed an increase in vasoconstrictor activity that had been masked by vasodilatory prostaglandin activity. In comparison, vasodilation to infused ME was significantly increased in uterine arteries from uninfected NP mice by either GB or whole intact mCMV pretreatment and was further increased in uterine arteries from in vivo mCMV-infected NP mice. In contrast, ME-induced vasodilation in uterine arteries from uninfected LP mice remained unaffected by GB or mCMV pretreatment but was significantly decreased in uterine arteries from mCMV-infected LP mice. Therefore, in addition to the vascular dysfunction observed during a full in vivo mCMV infection, these results demonstrate that viral attachment/early entry alone also differentially affects mesenteric and uterine arterial function in NP and LP mice through distinct mechanisms. These observations are important to take into consideration under conditions where latent infections are reactivated leading to viremia and also during administration of vaccines involving GB, both of which could directly affect endothelial function and vascular tone.
In mesenteric arteries, there were no differences in vasodilation responses to infused ME among groups; however, inhibition of prostaglandin/prostanoid production or the TBXA2 receptor revealed an otherwise masked increase in vasoconstrictor activity in both GB-treated arteries and arteries from mCMV-infected mice. In our previous study, vasodilation induced by extraluminal addition of ME was increased in mesenteric arteries from mCMV-infected mice in part through an increased contribution of nitric oxide (NO), which masked TBXA2/PGH2-induced vasoconstriction that contributed to the vascular tone [10] . In our current study, we saw no increase in vasodilation, but by blocking PTGS1/2 or the TBXA2 receptor, we observed increased vasodilation to infused ME in GBtreated mesenteric arteries from uninfected mice and in arteries from in vivo mCMV-infected mice compared to controls. This suggests that during active CMV infections, the systemic vasculature may be predisposed to increased vasoconstriction. Up to 70% of the antibodies from HCMV-seropositive individuals are GB specific [37] . As such, GB is a prime candidate for HCMV vaccine development and is currently in clinical trials [19, 29] . However, our results indicate that GB FIG. 2. Effect of prostaglandin inhibition or thromboxane receptor antagonism on vasodilation in mesenteric arteries after short-term pretreatment with GB. Arteries were dissected from uninfected NP (A) and LP (B) mice and treated with or without 1 lg/ml GB or were dissected and untreated from mCMVinfected NP and LP mice as described in Figure 1 . Vasodilation was induced by infusion of 1 lM ME into preconstricted mesenteric arteries in the presence or absence of meclofenamate (meclo) or SQ29548 for 30 min-1 h. ME data were taken from the curves in Figure 1 . Data were expressed as the mean 6 SEM percent increase in arterial lumen diameter compared to the passive lumen diameter in the presence of Ca 2þ -free medium and papaverine. A significant difference between the bars in each pretreatment group was determined by one-way ANOVA and Bonferroni post hoc analysis and symbolized with an a, b, or c (P , 0.05). n ¼ 4-5 animals.
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treatment changes the balance in prostanoid activity to favor vasoconstriction, and this may contribute to hypertensive disorders. This suggests that primary infections, reactivation of latent infections, and GB-based vaccines may also lead to vascular dysfunction and should be further investigated.
In this study, we use the pressure myograph to infuse the GB or mCMV pretreatments as well as the endothelialdependent vasodilator ME inside of the pressurized artery (intraluminal addition), allowing interaction with the endothelium directly. This is a more physiological method of measuring the response to circulating or endothelium-derived vasodilators. This differs from the approach used in our previous studies and in many studies in the literature where vascular agonists were applied extraluminally, which is more representative of vasodilatory mediators released from surrounding tissue and/or parasympathetic or sympathetic innervation of vascular smooth muscle cells. In contrast to our published results showing increased vasodilation in mesenteric arteries from mCMV-infected NP and LP mice, when ME was added to the bath (extraluminal) [11] , we showed no reduced, leading to decreased intraluminal application of ME in mesenteric arteries from mCMV-infected compared to uninfected mice. One explanation for these disparate results is that when ME is added extraluminally to the bath, access to the endothelial cells through the smooth muscle cell layers is reduced, leading to decreased muscarinic receptor interaction by ME on the endothelium (Fig. 4) . Therefore, intracellular calcium levels, activation of phospholipase A 2 (PLA 2 ), and secretion of arachidonic acid into the cytoplasm of endothelial cells are decreased, reducing prostanoid synthesis [38] . Although NO synthase is still activated with low intracellular calcium levels, leading to NO production, less TBXA2/PGH2 will be produced, leading to greater vasodilation and reduced vascular tone. In comparison, intraluminal infusion of ME may activate more muscarinic receptors on the endothelium via direct endothelium access, leading to increased intracellular calcium concentrations and maximal PLA 2 activity (Fig. 4)  [38] . Using the TBXA2 receptor antagonist and PTGS1/2 inhibitor, our study found that intraluminal ME infusion increases TBXA2/PGH2 activity and increases vascular tone in GB-treated mesenteric arteries from uninfected mice and in arteries from mCMV-infected mice compared to controls. The levels of vasodilation reached after inhibition of PTGS1/2 or antagonism of the TBXA2 receptor were similar to that observed in mesenteric arteries from mCMV-infected mice in previous studies where ME was applied extraluminally [10, 11] . This suggests that opposing vascular responses following intraluminal versus extraluminal drug addition reflect differences in ligand-receptor interactions on the luminal versus abluminal side of the endothelium, respectively, leading to differences in intracellular signaling and vascular tone (Fig. 4) . These differences in vascular results based on the use of methodology that directly impacts endothelial cells compared to smooth muscle cells are essential to correctly understand regulation of vascular tone.
In contrast to that found in mesenteric arteries, uterine arteries from uninfected NP mice treated for 1 h with GB or whole intact mCMV showed significant increases in sensitivity to infused ME. This increase was, however, less than the increase observed in uterine arteries from NP mice with a full in vivo mCMV infection. We previously demonstrated that the increased vasodilation in response to extraluminal application of ME observed in uterine arteries from mCMV-infected mice [11] could in part be explained by an increased sensitivity to NO in vascular smooth muscle cells [10] . It is likely that increased sensitivity of vascular smooth muscle cells to NO could also account for increased vasodilation after short-term GB or mCMV treatment of arteries from uninfected mice. In contrast with the increased vasodilation in arteries from NP mice, vasodilation to infused ME was decreased in uterine arteries from mCMV-infected LP mice, which could not be explained by differences in the NO or prostaglandin pathways [10] . The reduced vasodilation may contribute to reduced placental perfusion and IUGR associated with a HCMV infection [39] . Further investigation into the mechanistic differences in cholinergic vasodilation in GB-treated and untreated uterine arteries and uterine arteries from in vivo mCMV-infected mice is required to identify which signaling FIG. 3 . Effect of short-term pretreatment of pressurized uterine arteries with GB or whole intact mCMV on vasodilation induced by infusion of ME. Uterine arteries dissected from NP (A) and LP (B) mice were left untreated or treated as described in Figure 1 . Data were expressed and summarized as in Figure 1 . A significant difference between the bars at each ME concentration was determined by one-way ANOVA and Bonferroni post hoc analysis and symbolized with an a, b, or c (P , 0.05). n ¼ 3-9 animals.
VASCULAR DYSFUNCTION BY ENDOTHELIAL BINDING OF CMV molecules are affected. To begin to delineate the vasodilatory signaling pathway in uterine arteries that is affected by GB treatment or in vivo mCMV infection, we infused bradykinin, a potent vasodilatory peptide produced in both the nervous and cardiovascular systems whose receptor stimulates similar signaling pathways as the muscarinic receptors. Like the muscarinic receptor M 3 , the constitutively expressed bradykinin receptor B 2 is present on both the vascular endothelial and the smooth muscle cells and is also coupled to the Ga q/11 protein [40, 41] . We found that the effects of GB treatment or in vivo mCMV infection on uterine vasodilation were specific to the cholinergic system and were not observed with infusion of bradykinin. The lack of change in bradykinin-induced vasodilation suggests that the increased vasodilation in uterine arteries from mCMV-infected NP mice and decreased vasodilation in uterine arteries from mCMV-infected LP mice is specific to cholinergic agonists and muscarinic receptors, although the short timing of GB or mCMV treatment in arteries from uninfected mice precludes changes in receptor expression.
These results and those we have previously published demonstrate that although viral attachment/early entry alone is enough to induce changes that increase vasodilation in uterine arteries from NP but not LP mice, a full systemic infection can exacerbate these vascular changes or in the case of LP mice reduce vasodilation where there are no effects of attachment or early entry alone. Thus, in NP women, GB treatment may actually improve vasodilation in uterine arteries; increased uterine vasodilation and blood flow have been associated with increased fertility [42] . Nevertheless, this could be at the expense of increased vasoconstrictor activity in systemic arteries. In addition, during pregnancy, GB treatment does not affect uterine vasodilation to infused ME and likely has no impact on uterine blood flow. However, as in NP mice, GB treatment is also associated with increased vasoconstrictor activity in systemic arteries during pregnancy. Together, this suggests that although fertility may improve in women with GB treatment, they may be more susceptible to preeclampsia, a hypertensive disorder of pregnancy.
One limitation of our study is the comparison of GB protein treatment to that of whole intact virus. Whole intact virus contains several glycoproteins that may complement the activities of GB, such as the GM/GN heterodimer and the GH/GL/GO heterotrimer involved in cell attachment and entry, respectively [16] . Isaacson and Compton [17] illustrated with a GB deletion virus that GB is necessary for HCMV-cell fusion and infection but is not essential for initial virus-cell attachment. Thus, changes to vascular function through attachment and early entry events could conceivably occur through these other glycoproteins as well as GB. Nevertheless, much of the CMV vaccine development research has focused largely on GB expression and production. Therefore, we felt it was very important to study its physiological role in vascular reactivity and to evaluate the effects of whole intact virus at an early stage compared to that found following a fully systemic infection. Our present results are important to the study of GB vaccines in pregnant and nonpregnant individuals. However, further exploration of the vascular effects of other mCMV glycoproteins using GB-null virions, other herpesviruses, and unrelated viruses and long-term exposure of intact pressurized arteries to infused whole intact infectious mCMV to allow infection to take place are clearly important and would confirm if GB is both sufficient and necessary for changes in vascular responses.
Our study is the first to illustrate that a short-term exposure of endothelium in intact arteries to GB or whole intact CMV leading to direct cell attachment/early entry affects vascular responses independent of the effects induced by a full CMV infection. These novel results are particularly important to FIG. 4 . Schematic representation of a mesenteric artery from a mCMV-infected mouse. Proposed mechanism for differences in vasodilation response in mesenteric arteries from mCMV-infected mice after extraluminal addition (based on results from Gombos et al. [11] ) or intraluminal infusion of ME (current study). VSMC, vascular smooth muscle cells; EC, endothelial cells; AA, arachidonic acid; TBXA2, thromboxane; NOS, nitric oxide synthase; NO, nitric oxide; cGMP, cyclic guanosine monophosphate.
consider in medical conditions leading to viral reactivation with viremia and use of GB-based vaccines. The different effects on systemic versus uterine vascular health may impact the use of GB-based vaccines, particularly during pregnancy. It is important to note that vascular responses differ based on reproduction state, the extent and timing of viral challenge, vascular origin, and vascular mediator. In vivo mCMV infections exacerbate these direct viral effects and can cause further endothelial dysfunction, such as the significantly reduced endothelium-dependent vasodilation seen in uterine arteries from mCMV-infected LP mice. Indirect effects of an in vivo mCMV infection, such as production of immune response mediators, must still be studied. Each of these aspects must be considered for the development of potential therapeutics for specific vascular diseases associated with a CMV infection.
